Version 1
: Received: 26 August 2024 / Approved: 26 August 2024 / Online: 26 August 2024 (15:28:06 CEST)
How to cite:
de Andrade, A. P.; de Meneses, J. P.; Suss, P. H.; Ortis, G. B.; Tuon, F. F. Evaluating the Efficacy of Delafloxacin and Combination Therapy Against Staphylococcus aureus Biofilms: Insights into Activity in Acidic Environments. Preprints2024, 2024081870. https://doi.org/10.20944/preprints202408.1870.v1
de Andrade, A. P.; de Meneses, J. P.; Suss, P. H.; Ortis, G. B.; Tuon, F. F. Evaluating the Efficacy of Delafloxacin and Combination Therapy Against Staphylococcus aureus Biofilms: Insights into Activity in Acidic Environments. Preprints 2024, 2024081870. https://doi.org/10.20944/preprints202408.1870.v1
de Andrade, A. P.; de Meneses, J. P.; Suss, P. H.; Ortis, G. B.; Tuon, F. F. Evaluating the Efficacy of Delafloxacin and Combination Therapy Against Staphylococcus aureus Biofilms: Insights into Activity in Acidic Environments. Preprints2024, 2024081870. https://doi.org/10.20944/preprints202408.1870.v1
APA Style
de Andrade, A. P., de Meneses, J. P., Suss, P. H., Ortis, G. B., & Tuon, F. F. (2024). Evaluating the Efficacy of Delafloxacin and Combination Therapy Against Staphylococcus aureus Biofilms: Insights into Activity in Acidic Environments. Preprints. https://doi.org/10.20944/preprints202408.1870.v1
Chicago/Turabian Style
de Andrade, A. P., Gabriel Burato Ortis and Felipe Francisco Tuon. 2024 "Evaluating the Efficacy of Delafloxacin and Combination Therapy Against Staphylococcus aureus Biofilms: Insights into Activity in Acidic Environments" Preprints. https://doi.org/10.20944/preprints202408.1870.v1
Abstract
Background: Staphylococcus aureus is a major contributor to biofilm-associated infections, which complicate the treatment of chronic conditions like osteomyelitis and prosthetic infections. Bio-films, characterized by bacterial communities encased in a protective matrix, hinder the effec-tiveness of antimicrobial agents and contribute to persistent infections. Objective: This study aimed to evaluate the activity of delafloxacin, a novel fluoroquinolone, against biofilm-forming S. aureus strains, including methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) isolates. Methods: Delafloxacin’s efficacy was compared with traditional antibiotics (vancomycin, line-zolid, doxycycline, sulfamethoxazole/trimethoprim, and rifampicin) using minimal inhibitory concentration (MIC) assays, including testing at different pH levels to simulate acidic biofilm conditions. Synergistic interactions between delafloxacin and other antimicrobials were assessed using the checkerboard method. Biofilm eradication was tested through minimal biofilm eradi-cation concentration (MBEC) assays, biomass quantification, and cell viability (MTT assay). Re-sults: The results showed that all isolates were susceptible to vancomycin and linezolid, with varying resistance to other antibiotics. Delafloxacin demonstrated potent activity, with MIC re-ductions observed in acidic conditions. Synergistic effects were minimal, with only a few isolates showing synergy with vancomycin and doxycycline. Biofilm eradication tests revealed limited success in eradicating biofilms at breakpoint concentrations. However, rifampicin in combination with delafloxacin significantly reduced biofilm biomass in some isolates. No significant changes in cell viability were noted across treatments. Conclusion: This study highlights delafloxacin's potential against biofilm-associated infections, particularly in acidic environments. Despite the challenges in biofilm eradication, delafloxacin combined with rifampicin shows promise for im-proved treatment strategies.
Medicine and Pharmacology, Pharmacology and Toxicology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
